Identification of Siglec-1 null individuals infected with HIV-1 by Martínez Picado, Francisco Javier et al.
ARTICLE
Received 24 Feb 2016 | Accepted 30 Jun 2016 | Published 11 Aug 2016
Identiﬁcation of Siglec-1 null individuals infected
with HIV-1
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Margalida Rotger7, Judith Dalmau1, Dan Ouchi1, Steven M. Wolinsky8, Sudhir Penugonda8,
Huldrych F. Gu¨nthard9,10, Jacques Fellay11,12, Mary Carrington6,13, Nuria Izquierdo-Useros1,** & Amalio Telenti14,**
Siglec-1/CD169 is a myeloid-cell surface receptor critical for HIV-1 capture and infection of
bystander target cells. To dissect the role of SIGLEC1 in natura, we scan a large population
genetic database and identify a loss-of-function variant (Glu88Ter) that is found in B1% of
healthy people. Exome analysis and direct genotyping of 4,233 HIV-1-infected individuals
reveals two Glu88Ter homozygous and 97 heterozygous subjects, allowing the analysis of
ex vivo and in vivo consequences of SIGLEC1 loss-of-function. Cells from these individuals are
functionally null or haploinsufﬁcient for Siglec-1 activity in HIV-1 capture and trans-infection
ex vivo. However, Siglec-1 protein truncation does not have a measurable impact on HIV-1
acquisition or AIDS outcomes in vivo. This result contrasts with the known in vitro functional
role of Siglec-1 in HIV-1 trans-infection. Thus, it provides evidence that the classical HIV-1
infectious routes may compensate for the lack of Siglec-1 in fuelling HIV-1 dissemination
within infected individuals.
DOI: 10.1038/ncomms12412 OPEN
1 AIDS Research Institute IrsiCaixa, Institut d’Investigacio´ en Cie`ncies de la Salut Germans Trias i Pujol (IGTP), Universitat Auto`noma de Barcelona, 08916
Badalona, Spain. 2 Institucio´ Catalana de Recerca i Estudis Avanc¸ats (ICREA), 08010 Barcelona, Spain. 3 University of Vic-Central University of Catalonia
(UVic-UCC), 08500 Vic, Barcelona, Spain. 4 National HIV and Retrovirology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada R3E 0W3.
5Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada R3E 0J9. 6 Cancer and Inﬂammation Program,
Laboratory of Experimental Immunology, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702,
USA. 7 Institute of Microbiology, University Hospital Center and University of Lausanne, 1011 Lausanne, Switzerland. 8Department of Medicine, Northwestern
University Feinberg School of Medicine, Chicago, Illinois 60611, USA. 9 Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich,
University of Zurich, 8091 Zurich, Switzerland. 10 Institute of Medical Virology, University of Zurich, 8057 Zurich, Switzerland. 11 School of Life Sciences, E´cole
Polytechnique Fe´de´rale de Lausanne, 1015 Lausanne, Switzerland. 12 Swiss Institute of Bioinformatics, 1015 Lausanne, Switzerland. 13 Ragon Institute for MGH,
MIT and Harvard, Cambridge, Massachusetts 02139, USA. 14 Genomic Medicine, J. Craig Venter Institute, La Jolla, California 12037, USA. * These authors
contributed equally to this work. ** These authors jointly supervised this work. Correspondence and requests for materials should be addressed to
J.M.-P. (email: jmpicado@irsicaixa.es) or to N.I.-U. (email: nizquierdo@irsicaixa.es) or to A.T. (email: atelenti@jcvi.org).
NATURE COMMUNICATIONS | 7:12412 | DOI: 10.1038/ncomms12412 | www.nature.com/naturecommunications 1
A
ntigen presenting cells of the myeloid lineage, such as
monocytes, macrophages and dendritic cells, initiate
immune responses and are crucial to control invading
viruses. In the case of HIV-1 infection, however, myeloid cells
also promote viral pathogenesis through trans-infection of CD4þ
T cells1,2. This mechanism involves HIV-1 capture by sialic
acid-binding Ig-like lectin 1 (Siglec-1/CD169), a myeloid-cell
receptor that recognizes viral membrane gangliosides3–6. Viral
capture facilitates the release of trapped viruses at a cell-to-cell
contact zone promoting the trans-infection of CD4þ T cells7.
Immune activating signals, such as interferon alpha (IFNa) or
bacterial lipopolysaccharide, are present throughout the course of
HIV-1 infection8 and induce Siglec-1 expression on myeloid
cells5,6,9. However, under these inﬂammatory conditions, DC-
SIGN and other C-type lectin receptors previously implicated in
HIV-1 trans-infection2,10 play a minor role in viral
transmission5,6,11. Thus, Siglec-1 is an important inducible
receptor that could accelerate HIV-1 transmission in lymphatic
tissues, where many T-cells are in contact with myeloid cells.
Recent studies performed in vivo in mouse models demonstrated
that the robust infection of retroviruses in secondary lymphoid
tissues requires Siglec-1 and does not rely on the mouse DC-
SIGN homolog12. Siglec-1 trans-infection, cell-free virus infection
and cell-to-cell viral transfer between infected and non-infected
cells are all important routes of viral dissemination. Yet, the
relative contribution of trans-infection to HIV-1 transmission
and AIDS disease progression remains unknown.
There has been considerable interest in using human genetic
diversity to dissect the role of various genes in defence against
pathogens in natura13. Recently, protein-truncating variants have
been catalogued in the human genome14–17. These are variants
that are likely to disrupt the function of the corresponding
allele18,19. The identiﬁcation of the CCR5D32 variant was pivotal
to understanding how human genetic variation contributes to
differences in susceptibility to HIV-1 infection20, equally affecting
all routes of viral spread.
Here, we aimed to identify SIGLEC1 null individuals to dissect
the speciﬁc contribution of trans-infection to HIV-1 pathogenesis
in vivo. We ﬁnd individuals with a speciﬁc loss-of-function
variant in SIGLEC1 gene that completely abrogates Siglec-1
receptor expression on primary monocytes and their capacity
to trans-infect HIV-1 ex vivo. Despite this ex vivo phenotype
there is a striking absence of marked differences in HIV-1
acquisition or clinical evolution of individuals carrying SIGLEC1
loss-of-function alleles.
Results
Genetic description of SIGLEC1 variants. We used data from
the Exome Aggregation Consortium (ExAc.broadinstitute.org) to
identify naturally occurring knockout mutations in SIGLEC1.
In that sample of B63,000 individuals we observed 70 protein
truncating variants, that is, stop-gain, frameshift or splice site
(Fig. 1). With the exception of rs150358287, a stop-gain
variant resulting in an early stop codon at amino acid position 88
(Glu88Ter), truncating variants are of very low frequency (o1%).
The Glu88Ter variant occurs in the second exon of SIGLEC1
(C to A transversion at position 3706494 on chromosome 20,
GRCh 38 build reference sequence) and is predicted to truncate
both major transcripts of SIGLEC1. The stop-gain allele is
found at highest frequency in individuals of European and South
Asian ancestry (B1.3%) and is rare or absent in African and East
Asian populations (o0.5%).
To assess the frequency distribution of this polymorphism in
an HIV-1-infected population, we combined genotype data from
exome sequencing (n¼ 392), exome chip (n¼ 2,212) and direct
genotyping (n¼ 1,129) in participants of the Swiss HIV Cohort
Study (SHCS). In 3,733 individuals whose clinical characteristics
are detailed in Table 1 (95% reported European ancestry), we
observed 85 Glu88Ter heterozygotes and 2 homozygotes for the
stop-gain variant (allele frequency¼ 1.2%). Thus, we identiﬁed
individuals in whom to assess the consequences of Siglec-1
haploinsufﬁciency and knockout in vivo and ex vivo.
Functional analysis of SIGLEC1 null variant. To conﬁrm that
Siglec-1 Glu88Ter homozygous individuals truly lack receptor
expression, we performed functional assays with cryopreserved
cells collected from individuals with all three possible genotypes.
We induced Siglec-1 expression in isolated monocytes using
IFNa and determined the absolute number of Siglec-1 antibody
binding sites per monocyte (Fig. 2a). Compared to individuals
homozygous for the common allele, heterozygous individuals
expressed approximately half of the amount of protein observed,
while null individuals showed only background expression levels
(Fig. 2a). Next, we analyzed the ability of monocytes to capture
ﬂuorescent HIV-1 virus-like particles (VLPs) displaying speciﬁc
gangliosides that are efﬁciently recognized by Siglec-1 (refs 3,4).
IFNa-activated monocytes from individuals with the common
allele showed the highest viral capture capacity followed by
heterozygous and then by null individuals (Fig. 2b), which
captured only residual levels of VLPs. To investigate whether this
binding was speciﬁc for Siglec-1, cells were pre-treated with a
monoclonal antibody (mAb) against Siglec-1. Treatment led to a
signiﬁcant reduction of VLP uptake in monocytes from common
allele and heterozygous individuals (Fig. 2b), while it had no
inhibitory effect on SIGLEC1 null individuals. The VLP uptake of
monocytes from distinct SIGLEC1 genotypes strongly correlated
with the mean number of Siglec-1 antibody binding sites per cell
(Fig. 2c). To assess the general HIV-1 transfer capacity of Siglec-1
compared to other possible receptors on IFNa-activated
monocytes from homozygous individuals, we pulsed cells with
equal amounts of infectious HIV-1NL4-3 in the presence or
absence of blocking mAbs and co-cultured them with a CD4þ
reporter cell line (Fig. 2d). Monocytes from individuals with the
common allele had higher capacity to trans-infect than did
SIGLEC1 null cells (Fig. 2d). Trans-infection was inhibited with a
mAb against Siglec-1, which had no blocking effect on SIGLEC1
null monocytes (Fig. 2d). Overall, these results indicated that
SIGLEC1 null individuals lack functional Siglec-1 expression and
HIV-1 trans-infection capacity, ruling out genetic compensation
mechanisms or a possible stop codon read-through that could
alleviate the null status21.
SIGLEC1 null variant in HIV-1 acquisition. We next tested for
an impact of the Glu88Ter variant on HIV-1 acquisition. Given
the population frequency differences at which this variant occurs,
we limited these analyses to 3,558 individuals of European
ancestry to prevent confounding. The working hypothesis is that
if Siglec-1 were essential for infection, homozygous Glu88Ter
would not be infected—at least via mucosal exposure. The
observation of two HIV-1-infected Glu88Ter homozygotes ruled
out a requirement for a functional Siglec-1 protein in HIV-1
acquisition (that is, it does not mirror the CCR5D32 effect
regarding R5-tropic virus infection). In addition, the observed
frequency of the Glu88Ter allele in the HIV-1-infected popula-
tion (1.2%) is nearly identical to the frequency in Europeans from
the ExAc sample (1.3%) and does not differ depending on route
of infection (1.15% parenteral, 1.2% sexual, P¼ 0.95). Taken
together, these results suggest that functional SIGLEC1 is not
required for HIV-1 acquisition regardless of route of exposure.
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SIGLEC1 null variant in HIV-1 progression. We assessed the
potential impact of the SIGLEC1 null variant on HIV-1 viral load
and disease progression. As shown in Fig. 3, the presence of one
or two copies of the Siglec-1 Glu88Ter allele had no impact on
plasma set point viral load (n¼ 2,243; Fig. 3a). Similarly, there
was no difference in CD4þ T-cell dynamics (n¼ 2,302; Fig. 3b)
or in CD4þ T-cell nadir. We also investigated the disease course
(viral RNA level and CD4þ T-cell counts) for the two
homozygous Glu88Ter individuals, which supported viral
replication (Fig. 3c). Finally, we assessed the impact of the
Glu88Ter variant on progression to AIDS (as deﬁned in 1987) in
the SHCS (Fig. 3d), where we analyzed 52 Glu88Ter heterozygous
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Figure 1 | Location and frequency of SIGLEC1 protein truncating variants. Protein domains are represented in different colours. Data from the Exome
Aggregation Consortium (exac.broadinstitute.org) identiﬁes 70 protein truncating variants in SIGLEC1 including 33 stop gain (red), 24 frameshift (yellow)
and 12 splice disrupting (blue) variants. Grey boxes indicate amino acid blocks encoded by each exon. With the exception of Glu88Ter, all
protein truncating variants occur at o1% frequency. Glu88Ter is located in the V-set domain of Siglec-1, the region that recognizes sialyllactose in
HIV-1 membrane gangliosides.
Table 1 | Clinical characteristics of the SHCS cohort.
Glu88Ter (homozygous and heterozygous) Glu88 (homozygous)
Male n; (%) 65 (74.7%) 2835 (77.7%)
Female n; (%) 22 (25.3%) 808 (22.3%)
Age median; (IQR) 46 (41–50) 47 (41–53)
Caucasian n; (%) 80 (94.1%) 3447 (95.3%)
Peak viremia median; (IQR) 168,423 (42,036; 440,051) 103,094 (31,314; 290,000)
CD4 nadir median; (IQR) 236 (118; 306) 225 (121; 323)
Mode of HIV-1 acquisition n; (%)
Heterosexual 25 (29.4%) 1,116 (30.7%)
Homosexual 39 (45.9%) 1,617 (44.7%)
Intravenous drug user 20 (23.5%) 764 (21.1%)
Other/unknown 1 (1.2%) 120 (3.3%)
IQR, interquartile range.
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and 1 homozygous individuals out of 2,511 individuals.
We performed the same analysis in an independent cohort
(the Multicenter AIDS Cohort Study, MACS) after genotyping
413 Caucasian HIV-1-infected individuals with documented
seroconversion date (Fig. 3e). In the MACS cohort, we identiﬁed
12 heterozygous individuals, but no homozygous Glu88Ter
individuals were found. Although there was a slow progression to
AIDS observed in both the SHCS and MACS cohorts for
Glu88Ter individuals, it did not reach statistical signiﬁcance.
Discussion
The identiﬁcation of two homozygous HIV-1-infected individuals
with a conﬁrmed loss-of-function variant in SIGLEC1, both of
whom were infected via mucosal exposure, indicates that Siglec-1
trans-infection is not indispensable to establish HIV-1 infection
through sexual contact. Thus, Siglec-1 independent mechanisms of
infection are sufﬁcient to support mucosal HIV-1 spread. In the
absence of trans-infection, the classical HIV-1 infectious routes,
including cell-free virus infection or cell-to-cell HIV-1 transmis-
sion, compensate for the lack of Siglec-1 and are able to fuel HIV-1
dissemination within infected individuals. This explains why we
did not identify marked differences in clinical evolution of
individuals with one or two copies of the Siglec-1 Glu88Ter allele.
Given the available sample size of this study and the low
Glu88Ter frequency, we can only rule out a large effect of this
allele on disease progression. Power simulations indicate that we
would need 410,000 samples to detect a relative risk of 5
(similar to the effect of B*57:01 on HIV-1 control) at Po0.05
under a recessive model. This sample size far exceeds even the
largest genome-wide studies of HIV-1 progression that comprises
B6,000 patients22, which unfortunately does not genotype the
Glu88Ter variant and cannot be used to accurately impute the
presence of this rare allele. In addition, given that the proposed
effect (if any) requires long-term follow-up off therapy
(410 years) it is extremely unlikely that a sufﬁcient sample
size could be reached to assess the long-term consequences of
this variant on HIV-1 disease. However, the identiﬁcation of
the functional consequences of the Glu88Ter allele might
encourage future genetic studies to include this variant and
complement our analyses.
These results in humans are in contrast to those observed in the
BLT humanized mouse model, where Siglec-1 blockade signiﬁ-
cantly lowered HIV-1 infection of splenocytes12. Discrepancies
could be attributed to the fact that our study mainly focused on
heterozygous Siglec-1 Glu88Ter individuals, which maintain
partial receptor expression and function. Yet, the clinical course
of the two homozygous individuals did not show any obvious
beneﬁt of absence of Siglec-1. Alternatively, differences with the
murine model could be due to the distinct timeframes analyzed in
each case. The murine study was limited to the early dynamics of
HIV-1 infection12, a phase that is missing from the clinical records
of most patients, including the two null-homozygous individuals
identiﬁed here. Hence, it will be important to determine if the lack
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Figure 2 | Siglec-1 expression and trans-infection across distinct SIGLEC1 genotypes. Monocytes were isolated and cultured 24 h in the presence of
1,000 Uml 1 of IFNa to induce Siglec-1 expression. (a) Quantiﬁcation of Siglec-1 expression levels assessed by ﬂow cytometry. Empty box represents
a repeat analysis of one Siglec-1 null homozygote. (b) Capture of ﬂuorescent HIV-1 VLPs by monocytes from distinct genotypes previously exposed to
isotype or a-Siglec-1 mAbs. Geometric mean ﬂuorescence intensity of monocytes not exposed to VLPs is also depicted to show the background levels of
the assay (empty bars). (c) Correlation between Siglec-1 expression levels and viral capture values of isotype-treated monocytes. (d) HIV-1 transmission to
a reporter CD4þ cell line from monocytes of opposing homozygous individuals pre-incubated with isotype or a-Siglec-1 mAbs. HIV-1 infection of reporter
cells was determined by induced luciferase activity. Data show mean relative light units and SEM of cells from two homozygous individuals with the
common allele and one Siglec-1 null homozygote.
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of Siglec-1 in humans impacts early viral kinetics. If that is the
case, current antiretroviral treatments implemented early after
infection could include Siglec-1 blocking agents to tackle multiple
infectious routes simultaneously and limit the settlement of viral
reservoirs. Importantly, the identiﬁcation of SIGLEC1 null
individuals in natura indicates that Siglec-1 could represent a
safe therapeutic target.
The analysis of loss-of-function variants serves to illuminate
in vivo mechanisms of disease. Recent whole-genome and -exome
sequencing initiatives indicate that protein truncating alleles can
be identiﬁed in a large proportion of human genes. We have
estimated that up to 85% of all human genes can be observed
carrying heterozygous variants17. There is strong evidence that
heterozygous loss-of-function in innate immunity genes is not
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Figure 3 | Analysis of association between Siglec-1 Glu88Ter and HIV-1 clinical outcomes in the absence of antiretroviral treatment. (a) Set point viral
load of individuals from the SHCS with or without the Glu88Ter allele (n¼ 2,243). (b) CD4þ T-cell count dynamics of individuals from the SHCS with or
without the Glu88Ter allele (n¼ 3,385). CD4þ T-cell counts (cellsmm 3) were binned using 500 days windows, counting backwards from the date of
antiretroviral treatment start or loss of follow-up. Median CD4þ T-cell values (lines) and interquartile ranges in each bin (shaded areas) are shown for
individuals carrying no copies (n¼ 3,305) or one copy (n¼ 78) of the Siglec-1 Glu88Ter allele. Actual CD4þ T-cell values are shown for the two Siglec-1
Glu88Ter homozygotes. (c) Plasma viral RNA level (cp ml 1) and CD4þ T-cell count (cells mm 3) dynamics of the two Siglec-1 Glu88Ter homozygotes.
The dates of ﬁrst HIV-1 positive report and of ART initiation are depicted. Open circles indicate negative values bellow the represented detection level. (d)
Time to AIDS measured in the SHCS cohort (n¼ 2,458 common allele Glu88; n¼ 53 Glu88Ter including 52 heterozygous and 1 homozygous individuals) or
(e) the MACS cohort (n¼401 common allele Glu88; n¼ 12 Glu88Ter which were all heterozygous).
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms12412 ARTICLE
NATURE COMMUNICATIONS | 7:12412 | DOI: 10.1038/ncomms12412 | www.nature.com/naturecommunications 5
compensated in the majority of cases16. Thus, the discovery and
characterization of human protein truncating variants serves as a
general model for the analysis of other human genes involved in
pathogen containment.
Methods
Patients. The Swiss HIV Cohort Study is an ongoing observational
longitudinal study enroling HIV-1-infected individuals since 1988 in Switzerland.
Demographic, route of transmission, clinical and laboratory data are systematically
collected, and plasma and cells are stored longitudinally every 6–12 months. To
date,419,000 patients have been enroled. At least 50% of all HIV-1-infected, 72%
of all AIDS cases in Switzerland are enroled23. The MACS24 is an ongoing
prospective study of the natural and treated histories of HIV-1 infection in
homosexual and bisexual men conducted by sites located in Baltimore, Chicago,
Pittsburgh and Los Angeles. A total of 6,972 men have been enroled. Clinical
characteristics of the Glu88Ter homozygous include a female diagnosed in 1987
that died in 2003 of Pneumocystis jirovecii infection and refused treatment. The last
CD4þ T-cell count was 8 cellsmm 3 and the last viremia recorded for this
individual was 4750,000 cpml 1. In 1994, she had an episode of pulmonary
tuberculosis. The second Glu88Ter homozygous is a male that was diagnosed
HIVþ in 1987 and registered in the SHCS in 1996, when he initiated antiretroviral
treatment while clinically asymptomatic. He has been on antiretroviral treatment
for most of the past 20 years (except for a short period in 2003 and 2004), with
stable CD4þ T-cell count between 400 and 600 cellsmm 3. Last clinical values
(recorded in October 2015) were a CD4þ T-cell count of 602 cellsmm 3 (23%)
and a viremia o20 cpml 1.
Ethics statement. The institutional review board on biomedical research from
Hospital Germans Trias i Pujol approved this study. Participants of the Swiss HIV
Cohort Study and the multicenter AIDS Cohort Study (MACS) consented to the
cohort study and genetic analyses, as approved by the corresponding local Ethics
Committees.
Primary cell culture. Frozen peripheral blood mononuclear cells were obtained
from HIV-1 patients of the Swiss HIV Cohort Study. Monocyte populations were
isolated using CD14 magnetic beads (Miltenyi Biotec) and cultured 24 h with
1,000Uml 1 of IFNa (Sigma) in RPM1 with 10% of heat-inactivated fetal bovine
serum (Invitrogen).
Siglec-1 surface expression analysis by FACS. IFNa-activated monocytes were
blocked with 1mgml 1 of human IgG (Baxter, Hyland Immuno) and stained with
1/10 dilution of a-Siglec-1-PE 7–239 mAb (AbD Serotec) following manufactures
instructions at 4 C for 20min. Samples were analyzed with FACSCalibur
(Becton-Dickinson) using CellQuest software to evaluate collected data. The mean
number of Siglec-1 Ab binding sites per cell was obtained with a Quantibrite kit
(Becton-Dickinson) as previously described5.
VLP capture and HIV-1 trans-infection assays. VLPHIV-Gag-eGFP and HIV-1NL4-3
were obtained by calcium phosphate transfection of previously described
plasmids5. IFNa-activated monocytes (2 105) were pre-incubated at 16 C for
30min with 10mgml 1 of a-Siglec-1 mAb (7–239, AbSerotec) or IgG1 isotype
control mAb (107.3, BD Bioscience). Capture experiments were performed pulsing
monocytes with 150 ng of VLPHIV-Gag-eGFP Gag for 3 h at 37 C. After extensive
washing, monocytes were acquired by FACS. Trans-infection assays were
performed pulsing monocytes with 300 ng of HIV-1NL4-3 for 4 h at 37 C. After
extensive washing, monocytes were co-cultured in duplicate at a ratio of 1:1 with
the TZM-bl CD4þ target cell line. Cells were assayed for luciferase activity 48 h
later (BrightGlo Luciferase System; Promega) in a Fluoroskan Ascent FL
luminometer (Thermo Labsystems).
Genetic analyses. For 392 participants from the SHCS, we captured and
sequenced all coding exons using the Illumina Truseq 65Mb enrichment kit and
the Illumina HiSeq2000. Sequences were aligned to the human reference genome
version 19 (GRCh 37) using BWA. Variant calling was performed using the
HaplotypeCaller module of the Genome Analysis Toolkit version 3.1–1. Only
variants passing the variant quality score recalibration thresholds were maintained
for further analysis. Genotype data for 2,212 individuals were obtained using the
Illumina Inﬁnium Human Exome BeadChip. Direct genotyping for
rs150358287G4T in 1,129 individuals from the SHCS and 425 individuals from
the MACS was performed by Taqman allelic discrimination using a custom design
assay from Applied Biosystems (AHKAY5K). Exome sequencing results were
conﬁrmed by PCR and direct sequencing (forward primer: 50 AGGACGTGCAGG
GTGTGAAG330; reverse primer: 50 GCTGGAACAGAGGCTGAGAC 30 ;
annealing temperature: 62 C; expected fragment: 455 bp).
Statistical analysis. Statistics of VLP functional assays were performed using
unpaired and paired t test (considered signiﬁcant at Pr0.05) or the Spearman
correlation with GraphPad Prism v.5 software. Set point viral load was calculated as
the average of at least three measurements obtained during the chronic phase of
infection (minimum 6 months after infection and before the initiation of anti-
retroviral therapy (ART)). A comparison of variance in set point viral load between
genotype groups showed no signiﬁcant differences (F test P¼ 0.18). Association
between viral RNA level and genotype was tested using linear regression. Rate of
disease progression was measured using all available CD4þ T-cell counts begin-
ning at enrolment or estimated date of infection (if known) before the initiation of
anti-HIV therapy. The impact of genotype on disease progression was tested using
the Cox proportional hazards models.
Data availability. The clinical and genetic data that support the ﬁndings of this
study are available on request from the corresponding authors; these data
are not publicly available due to information that could compromise research
participant privacy. The authors declare that all other data supporting the ﬁndings
of this study are available within the article or from the corresponding authors
upon request.
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